Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Risperdal Jury “Blown Away” By Testimony On Study Manipulation; J&J Settles Texas Suit

This article was originally published in The Pink Sheet Daily

Executive Summary

In the midst of a trial, Johnson & Johnson agrees to pay $158 million to settle a suit by the state of Texas alleging the company promoted Risperdal off-label to children. Two states previously won jury verdicts over the company’s marketing of the antipsychotic.

Advertisement

Related Content

J&J Challenges Risperdal Penalty As First Amendment Violation
FDA Warning Letter Is Inadmissible Hearsay, Arkansas Supreme Court Says In Tossing J&J Judgment
Pharma v. State AGs: GlaxoSmithKline Is Fifth Firm To Challenge Hiring Of Private Counsel
J&J Says Penalties In Arkansas Risperdal Case ‘Excessive,’ Seeks New Trial
J&J Ordered To Pay South Carolina $327 Million For "Detestable" Risperdal Marketing
States Reap Rewards From Solo Suits Against Pharma; Atypical Antipsychotics May Offer Test Cases
J&J "Dear Healthcare Provider" Letter On Risperdal Leads To $257.7 Million Jury Award

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel